洛铂与紫杉醇联合治疗晚期卵巢癌的临床观察

目的：观察洛铂与紫杉醇联合化疗治疗晚期卵巢癌的近期疗效及不良反应。方法：50例晚期卵巢癌（Ⅲ期或Ⅳ期）患者，其中26例患者采用洛铂＋紫杉醇静脉化疗，其中洛铂30mg／m2，d1天，紫杉醇135～175mg／m。dl天。24例患者采用顺铂＋紫杉醇静脉化疗，其中顺铂25mg／m2，d1-3天，紫杉醇135～175mg／m。dl天，2～4个疗程观察疗效。结果：26例洛铂组患者中，完全缓解7例，部分缓解8例，稳定9例，进展2例，有效率为57．7％。24例顺铂组患者中，完全缓解5例，部分缓解8例，稳定6例，进展5例，有效率为54．2％。主要毒副反应为骨髓抑制、骨骼酸痛、神经毒性和脱发。结论：洛铂联合紫杉醇治疗晚期卵巢癌疗效较好，毒副反应可以耐受。

Efficacy Observation of Lobaplatin and Paclitaxel Therapy in Recurrent Advanced Ovarian Carcinoma

Objective： To evaluate the effects of lobaplatin and paclitaxel on treating recurrent advanced ovarian carcinoma and their adverse reactions. Methods： A total of 50 patients （Ⅲ-Ⅳ） with recurrent advanced ovarian carcinoma were enrolled, including 26 cases of lobaplatin ＋ paclitaxel and 24 cases of cisplatin ＋ paclitaxel. Lobaplatin group（lobaplatin ＋ paclitaxel）： lobaplatin at a dose of 30 mg/m2 intravenous infusion on dl, and paclitaxel at a dose of 135- 175 mg/m2 intravenous infusion on day 1. Cisplatin group （cisplatin ＋ paclitaxel）： cisplatin at a dose of 24 mg/m2 intravenous infusion on dayl and paclitaxel at a dose of 135 - 175 mg/m2 intravenous infusion on dl. The efficacy was evaluated after 2-4 cycles. Results： Lobaplatin group： seven patients achieved complete response（CR）, eight pa- tients achieved partial response （PR）, nine patients achieved stable disease （SD） and two patients achieved progressed disease （PD）. The overall response rate （RR=CR＋PR） was 57.7 %. Cisplatin group： five patients achieved CR, eight patients achieved PR, six patients SD and five patients achieved PD. The overall response rate was 54.2 %. The major adverse effects were bone marrow depression, arthralgia, neurotoxicity and alopecia. Conclusion： Combined chemotherapy of lobaplatin and paclitaxel has a good anti-tumor activity and manage- able toxicity on recurrent advanced ovarian carcinoma patients.